JamesfromSG
2021-11-29
Nice! Managed to pick up a small portion of BioNTech. Better than nothing
Moderna stock surged 8% in premarket trading
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
8
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":600528120,"tweetId":"600528120","gmtCreate":1638177130925,"gmtModify":1638177131187,"author":{"id":4090044065782350,"authorId":4090044065782350,"authorIdStr":"4090044065782350","name":"JamesfromSG","avatar":"https://static.tigerbbs.com/d251750cfb493127443c3b9990000f69","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice! Managed to pick up a small portion of BioNTech. Better than nothing </p></body></html>","htmlText":"<html><head></head><body><p>Nice! Managed to pick up a small portion of BioNTech. Better than nothing </p></body></html>","text":"Nice! Managed to pick up a small portion of BioNTech. Better than nothing","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/600528120","repostId":1106015985,"repostType":4,"repost":{"id":"1106015985","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638176514,"share":"https://www.laohu8.com/m/news/1106015985?lang=&edition=full","pubTime":"2021-11-29 17:01","market":"us","language":"en","title":"Moderna stock surged 8% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1106015985","media":"Tiger Newspress","summary":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be re","content":"<p>Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.</p>\n<p><img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p>\n<p>Moderna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p>\n<p>\"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p>\n<p>\"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p>\n<p>\"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p>\n<p>The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p>\n<p>Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p>\n<p>\"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p>\n<p>The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p>\n<p>Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.</p>\n<p>Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p>\n<p>\"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock surged 8% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock surged 8% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-29 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.</p>\n<p><img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p>\n<p>Moderna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p>\n<p>\"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p>\n<p>\"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p>\n<p>\"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p>\n<p>The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p>\n<p>Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p>\n<p>\"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p>\n<p>The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p>\n<p>Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.</p>\n<p>Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p>\n<p>\"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106015985","content_text":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.\n\nModerna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.\n\"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.\n\"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.\n\"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.\nThe Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.\nProtection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.\n\"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"\nThe emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.\nFears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.\nModerna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.\n\"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":543,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":61,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/600528120"}
精彩评论